Global Short Bowel Syndrome Market Analysis & Forecast 2024-2034: Market By Drug Class; By Distribution Channel; and By Region

The global short bowel syndrome market size was estimated to be USD 0.997 billion in 2023 and is expected to reach at USD 4.75 billion by 2034 with a CAGR of 15.26% during the forecast period 2024-2034. Increasing prevalence of short bowel syndrome (SBS), rising prevalence of GI disorders such as volvulus, Crohn’s disease (CD), Inflammatory bowel disease (IBD), & mesenteric ischemia, growing awareness initiatives by private organizations, surge in launch of novel products, increasing research & development activities, and Rising initiatives for the development of novel therapies for SBS by market players are some of the key factors boosting the market growth.

Rising initiatives for the development of novel therapies for SBS by market players is predicted to boost the market growth during the forecast period. The increasing prevalence of SBSIF patients who rely heavily on parental support for essential fluids and nutrients has led to a surge in demand for innovative therapies. This rise in demand is a result of the growing number of SBS cases. For instance, in October 2022, VectivBio Holding AG has released favorable initial results from the ongoing Phase 2 STARS Nutrition study. This study is focused on assessing the safety, pharmacokinetics, and effectiveness of a new experimental drug called apraglutide. Apraglutide belongs to a class of drugs known as synthetic GLP-2 agonists and offers prolonged activity. The trial is being conducted in adult patients dealing with Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC).

By drug class, GLP-2 was the highest revenue-grossing segment in the global short bowel syndrome market in 2023 owing to the effectiveness of GLP-2 drugs in SBS, growing adoption of GLP-2 therapies in the management of SBS, surge in funding from the NIH for Crohn's disease, rising approvals of therapies, and increasing research & development activities for GLP-2 drugs for SBS. For instance, in September 2022, Zealand Pharma has announced encouraging outcomes from a phase 3 clinical trial involving Glepaglutide, a GLP-2 agonist, administered to patients with Short Bowel Syndrome (SBS). The trial concluded that the treatment exhibited both safety and favorable tolerability among the participants. Additionally, growth hormone is predicted to grow at fastest CAGR during the forecast period owing to the presence of approved drugs such as Zorbtive, benefits provided by insurance's medication coverage, and rising approval of short-term use drugs for treating SBS.

By distribution channel, online & retail pharmacies was the highest revenue-grossing segment in the global short bowel syndrome market in 2023 owing to the patients' referential migration to internet platforms, surge in number of online & retail pharmacies, and increasing collaborations within market players & online pharmacies. Additionally, hospital pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of SBS, rising demand for advanced drugs for the treatment, increase in the supply of drugs to hospital pharmacies, and surge in regulatory approvals. For instance, in June 2022, The National Institute for Health and Care Excellence (NICE), the organization responsible for evaluating health technologies in England and Wales, has endorsed the utilization of Takeda's Revestive (teduglutide). This recommendation pertains to the daily subcutaneous injection of the medication and is intended for individuals aged 1 year and older who are affected by Short Bowel Syndrome (SBS).

North America region is anticipated for the highest revenue share during the forecast period owing to the increasing prevalence of SBS, growing adoption of sedentary lifestyle, rising healthcare infrastructure, surge in funding from the government on the research of Crohn's disease, and increasing clinical trials by major market players. For instance, in June 2022, 9 Meters Biopharma, a company in the clinical development stage, has announced encouraging initial top-level findings from the phase II trial of VurolenatIde intended for Short Bowel Syndrome (SBS). Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising investment in research & development activities for the development of novel drugs, presence of leading market players, growing focus on clinical trial procedures on GLP-2-based drugs, increasing awareness regarding the disease among population, surge in demand for various advanced treatment options, and rising collaborations within market players. For instance, in March 2022, VectivBio AG has revealed a licensing deal with Asahi Kasei Pharma Corporation for the distribution and advancement of Apraglutide within Japan. Apraglutide is employed for the treatment of Short Bowel Syndrome (SBS).

Segmentation: Short Bowel Syndrome Market Report 2022 - 2033

Short Bowel Syndrome Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)

• Growth Hormone
• GLP-2
• Glutamine
• Others

Short Bowel Syndrome Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)

• Online & Retail Pharmacies
• Hospital Pharmacies

Short Bowel Syndrome Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

North America

• U.S.
• Canada

Europe

• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC

Latin America

• Brazil
• Mexico
• Argentina
• Rest of LATAM

Middle East & Africa

• South Africa
• GCC
• Rest of MEA